Abstract: A method of generating an induced trophoblast stem cell (iTSC) from a human cell is provided. Accordingly there is provided a method comprising expressing within a human cell GATA3 and OCT4 transcription factors, under conditions which allow generation of an iTSC from the cell. Also provided is a method of rejuvenating and/or de-differentiating a human cell. Also provided are nucleic acid constructs, protein preparation, isolated human cells, human iTSCs, rejuvenated cells and de-differentiated cells.
Type:
Application
Filed:
December 13, 2023
Publication date:
April 25, 2024
Applicant:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: The present invention relates to edible plant parts or tissues comprising probiotic bacteria and use thereof for oral delivery of the probiotic bacteria to an organism and enriching and/or improving the organism gastrointestinal tract microbiome. The present invention further relates to methods for selecting and/or producing probiotic bacteria capable of colonizing a plant tissue.
Type:
Grant
Filed:
April 10, 2019
Date of Patent:
April 16, 2024
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., OFEK—ESHKOLOT RESEARCH AND DEVELOPMENT LTD.
Abstract: The invention provides cannabinoid derivatives, methods of their preparation, compositions comprising them and uses thereof in the treatment of inflammation and/or pain and/or obesity.
Type:
Application
Filed:
November 24, 2021
Publication date:
April 11, 2024
Applicant:
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
Abstract: The present invention provides method for processing spin magnetometry data of a sample, said data generated with a point defects-based spin magnetometer, and for providing information on the presence and properties of a particular compound in the sample, wherein said method comprises: (1) Subjecting the sample to a spin magnetometry measurement with the point defects-based spin magnetometer to generate a string or an array of the spin measurement results of said sample, said string or an array of the spin measurement results is an input for an external memory; and (2) Applying a deep-learning method on said spin measurement results in the external memory to output a single bit whose value is ‘0’ or ‘1’, or an array of bits, or an array of integers, or an array of complex numbers, wherein said single bit, or said array of bits, or said array of integers, or said array of complex numbers corresponds to an estimated frequency and/or an amplitude of the input, thereby providing information on the presence and p
Type:
Grant
Filed:
September 5, 2019
Date of Patent:
April 9, 2024
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Inventors:
Alexander Retzker, Zohar Ringel, Netanel Aharon
Abstract: Disclosed are peptides that specifically bind to neutrophils and uses thereof for neutrophil-targeted delivery of drugs or diagnostic agents in medical conditions including cancer as well as infectious, inflammatory and autoimmune diseases or disorders.
Type:
Grant
Filed:
December 27, 2022
Date of Patent:
April 9, 2024
Assignees:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEIDCAL RESEARCH SERVICES & DEVELOPMENT LTD.
Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.
Type:
Application
Filed:
October 12, 2023
Publication date:
March 21, 2024
Applicant:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: The present invention provides a nanoparticle including: (a) an amphiphilic co-polymer including an ionizable polymer covalently bound to a hydrophobic domain; and a polynucleotide comprising 60 to 500 nucleobases. Further provided are compositions including the nanoparticle of the invention, and methods of using same.
Type:
Application
Filed:
January 20, 2022
Publication date:
March 21, 2024
Applicants:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
Abstract: The present invention provides nanoparticle carriers of active agents which are functionalized by stimuli-responsive conjugation with DNA-nano structures, methods and processes for their preparation, compositions comprising them and uses thereof in methods of treating diseases, disorders and symptoms thereof.
Type:
Application
Filed:
January 17, 2022
Publication date:
March 14, 2024
Applicant:
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
Inventors:
Itamar WILLNER, Eli PIKARSKY, Rachel NECHUSHTAI, Yang-Sung SOHN, Pu ZHANG, Yu OUYANG
Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
Type:
Grant
Filed:
March 29, 2021
Date of Patent:
March 12, 2024
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
Inventors:
Yinon Ben-Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph P. Vacca, Dansu Li
Abstract: Provided are novel compounds and uses thereof in preventing antifouling by unicellular organisms and in attracting cells from multicellular organisms.
Type:
Grant
Filed:
September 7, 2016
Date of Patent:
March 12, 2024
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: Provided are in-vitro methods and devices for sustaining a synchronized circadian rhythm in cells of a cell culture by exposing the cells to a continuous flow of medium and to at least two stimuli provided in an oscillating manner with a periodicity of 24±4 hours, wherein a first stimulus and a second stimulus of said at least two stimuli are distinct, wherein said first stimulus is provided in a first time period and reaches a first peak in a first peak time period, and wherein a second stimulus is provided in a second time period and reaches a second peak in a second peak time period, and wherein an interval between end of time period of said first peak and beginning of said time period of said second peak is at least about 2 hours.
Type:
Grant
Filed:
June 19, 2020
Date of Patent:
February 27, 2024
Assignee:
Yissum Research Development
Company of the Hebrew University of Jerusalem Ltd.
Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.
Type:
Grant
Filed:
July 15, 2021
Date of Patent:
February 27, 2024
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of a disorder associated with binding of IGF2BP1 to an RNA in a subject in need thereof are also provided.
Type:
Application
Filed:
November 18, 2021
Publication date:
January 25, 2024
Applicants:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., THE PENN STATE RESEARCH FOUNDATION
Inventors:
Vladimir SPIEGELMAN, Vikash SINGH, Arun SHARMA, Amandeep SINGH, Joel YISRAELI, Nadav WALLIS, Froma OBERMAN
Abstract: The present invention provides monoclonal antibodies that recognize poliovirus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
Type:
Application
Filed:
August 15, 2023
Publication date:
January 18, 2024
Applicants:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., UNIVERSITY OF RIJEKA FACULTY OF MEDICINE
Inventors:
Ofer MANDELBOIM, Noa S. KAYNAN, Pinchas TSUKERMAN, Stipan JONJIC
Abstract: A method of selecting an agent for treating a disease of a subject is disclosed which includes identifying genes which bring about resistance to a cytotoxic agent in haploid human embryonic stem (ES) cells. Once the gene is identified, the method includes analyzing the sequence and/or expression of the gene in a cell sample of the subject, wherein an alteration in the sequence and/or level of expression of the gene as compared to the sequence and/or expression of the gene in a control sample is indicative that the agent should be ruled out as a monotherapy for treating the disease in the subject.
Type:
Grant
Filed:
June 19, 2016
Date of Patent:
January 2, 2024
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: A method of increasing milk secretion of a predetermined milk component from a tissue culture comprising mammary epithelial cells (MECs) is provided. The method comprising admixing into a medium composition comprising the tissue culture, a biologically effective concentration of a composition selectably operable to increase the secretion of the predetermined components, the composition comprising at least one agent selected from the group consisting of oleic acid, beta-hydroxybutirate (BHBA) and a phenolic composition, wherein the agent is not an ethanol extract of P. lentiscus; and when the agent comprises oleic acid it comprises at least two of the agents.
Type:
Application
Filed:
September 14, 2023
Publication date:
December 28, 2023
Applicants:
Wilk Technologies International Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
Type:
Grant
Filed:
October 8, 2020
Date of Patent:
December 12, 2023
Assignees:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., University of Jerusalem Ltd.
Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
November 21, 2023
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.